During the past decade, UCLA David Geffen School of Medicine, Division of Rheumatology conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 8 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UCLA David Geffen School of Medicine, Division of Rheumatology" #1 sponsor was "University of California, Los Angeles" with 6 trials, followed by "Hoffmann-La Roche" with 2 trials sponsored, "Veena Ranganath, MD, MS" with 2 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UCLA David Geffen School of Medicine, Division of Rheumatology" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator and "Novartis Pharmaceuticals" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "UCLA David Geffen School of Medicine, Division of Rheumatology" are "Rheumatoid Arthritis" (5 trials), "Systemic Sclerosis" (2 trials), "Alveolitis" (1 trials), "Cannabis" (1 trials) and "Giant Cell Arteritis" (1 trials). Many other conditions were trialed in "UCLA David Geffen School of Medicine, Division of Rheumatology" in a lesser frequency.

Most popular intervention types in "UCLA David Geffen School of Medicine, Division of Rheumatology" are "Drug" (11 trials), "Biological" (2 trials), "Behavioral" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Tocilizumab" (3 trials), "Prednisone" (2 trials), "200mg Cannabidiol by capsules twice daily" (1 trials) and "400mg Cannabidiol by capsules twice daily" (1 trials). Other intervention names were less common.

The vast majority of trials in "UCLA David Geffen School of Medicine, Division of Rheumatology" are 12 trials for "All" genders.

Currently, there are NaN active trials in "UCLA David Geffen School of Medicine, Division of Rheumatology". undefined are not yet recruiting, 2 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in UCLA David Geffen School of Medicine, Division of Rheumatology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in UCLA David Geffen School of Medicine, Division of Rheumatology, 3 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 1 trials that are defined as “Not Applicable".